Fig. 3.

Cell viability following combination treatment with irinotecan and anti-human DLL4 therapeutic antibody or irinotecan and ABL 001 antibody in GC cells (A, B) AGS and MKN28 cells were treated with 1 µM irinotecan alone, a combination of irinotecan (0.5 µM) and anti-hDLL4 (25 nM), or irinotecan (0.5 µM) and ABL001 (25 nM) for 24 h. (A) WST assays were performed to detect the cell viability. (B) Invasion ability of the cells was analyzed using Transwell chamber assay. (C, D) AGS and MKN28 cells were grown under 3D-culture conditions and the sphere-forming ability was measured after 15-days of treatment. Cells were treated with 1 µM irinotecan alone, a combination of irinotecan (0.5 µM) and anti-hDLL4 (25 nM), or irinotecan (0.5 µM) and ABL001 (25 nM) every 3 days. *P < 0.05, **P < 0.01, and *** P < 0.001.